CHINA PHARMA HOLDINGS, INC. Long-term Line of Credit
CHINA PHARMA HOLDINGS, INC. (CPHI) had Long-term Line of Credit of CNY 3.80 million as of 2023-12-20, per its 10-K filed 2024-04-01.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2024-04-01
- 2022-12-30: Long-term Line of Credit $560.00K.
- 2022-12-21: Long-term Line of Credit $1.00M.
- 2021-09-18: Long-term Line of Credit $1.54M; Long-term Line of Credit as first filed $1.40M.
- 2015-11-30: Long-term Line of Credit $4.50M.
USD
| Period end | Long-term Line of Credit | Long-term Line of Credit as first filed |
|---|---|---|
| 2022-12-30 | $560.00K 10-K · filed 2024-04-01 | |
| 2022-12-21 | $1.00M 10-K · filed 2024-04-01 | |
| 2021-09-18 | $1.54M 10-K · filed 2024-04-01 | $1.40M 10-Q · filed 2023-11-13 |
| 2015-11-30 | $4.50M 10-K · filed 2018-04-02 | |
| 2014-11-30 | $4.50M 10-K · filed 2018-04-02 |
CNY
| Period end | Long-term Line of Credit |
|---|---|
| 2023-12-20 | 3.80M CNY 10-K · filed 2024-04-01 |
| 2022-12-30 | 3.80M CNY 10-K · filed 2024-04-01 |
| 2022-12-21 | 7.30M CNY 10-K · filed 2024-04-01 |
| 2021-09-18 | 10.00M CNY 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |